HEOR

News

NICE backs Roche's non-Hodgkin lymphoma drug Columvi

NICE backs NHS use of Roche's Columvi as a second-line therapy for a form of non-Hodgkin lymphoma affecting thousands of people in the UK each year.

News

"Significant shift" as NICE widens prostate cancer drug use

NICE has changed unpopular guidance on abiraterone for hormone-sensitive prostate cancer after the entry of generics into the UK market.

News

A male HCP discusses treatment with an older male patient

Bayer's prostate cancer drug Nubeqa cleared for NHS use

Thousands of men living with incurable prostate cancer will be able to access an easier-to-tolerate treatment from Bayer, thanks to new NICE guidance.

News

ICER says US new drug launch prices have risen sharply

ICER says the prices of new drug launches in the US rose 51% in three years, adding up to $1.5bn in first-year costs to US health systems.

News

ViiV's bimonthly HIV PrEP jab cleared for use by NHS

ViiV's injectable HIV PrEP Apretude will soon be an alternative for people in England and Wales who cannot use daily oral options.

News

Pharmacist shelving medicine in pharmacy

NHS could pay more for medicines under new plan

Changes to the threshold used by NICE to measure cost-effectiveness could be on the way as part of a plan that would raise NHS spending on medicines.

NICE backs Roche's non-Hodgkin lymphoma drug Columvi

"Significant shift" as NICE widens prostate cancer drug use

Bayer's prostate cancer drug Nubeqa cleared for NHS use

ICER says US new drug launch prices have risen sharply

ViiV's bimonthly HIV PrEP jab cleared for use by NHS

NHS could pay more for medicines under new plan

Agios mulls early FDA filing for sickle cell therapy

Using AI-driven synthetic personas to take your insights fur...

HEOR

Editor's Picks